|By PR Newswire||
|April 10, 2014 07:00 AM EDT||
DUODOPA improves quality of life for those with advanced stages of disease
MONTREAL, April 10, 2014 /CNW/ - AbbVie today announced that a new treatment called DUODOPA® (levodopa/carbidopa intestinal gel) is now available to Canadians with advanced Parkinson's disease. Currently, more than 100,000 Canadians live with Parkinson's – a progressive, incurable neurological disorder that can significantly affect the quality of life of patients, their families and caregivers.
DUODOPA is approved in Canada for the management of advanced Parkinson's disease in adults with severe, disabling motor fluctuations and hyper-/dyskinesia (involuntary movements) not satisfactorily controlled by combinations of available oral medicinal products for Parkinson's disease.
"A major problem that emerges over time in people with Parkinson's disease is fluctuations in their ability to move due to unreliable absorption of oral medications. This leads to inconsistent delivery of the chemical dopamine which controls movement to the brain resulting in unpredictable motor function," said Dr. Anthony Lang of the Movement Disorder Centre at Toronto Western Hospital, University Health Network, which is one of four centers of excellence in Canada to treat advanced Parkinson's patients with this new treatment. "DUODOPA is a treatment option that enables patients to regain control over their movements and balance which in turn drastically improves their quality of life."
Parkinson's disease, which involves significant loss of limb and balance control, is most commonly diagnosed at 50-60 years of age – although diagnosis can occur at a much younger age. The standard treatment for Parkinson's disease begins with oral therapies, including levodopa, which usually work well during the first years. As the disease progresses, oral therapies no longer provide satisfactory control over severe motor fluctuations and dyskinesia. Now with DUODOPA there is a new option.
"I am a writer and I could not write. I would have very painful tremors in my right hand and rigidity on my entire left side," said Doug Curtis, a playwright who has been living with Parkinson's disease for 10 years. He is one of the first Parkinson's patients in North America to receive DUODOPA. "Parkinson's took away my ability to express myself. But now I can write again. The tempo of my life has returned. I now have the confidence to take on Parkinson's head on."
"My husband was progressively getting worse as he moved into the advanced stages of the disease. Simple daily tasks became a challenge and he became dependent on me," said Heather Moore, Doug's wife and caregiver. "Today, I see Doug's condition improving and because of this progress my family has regained a sense of normalcy in our lives."
About Parkinson's Disease (PD)
PD is a progressive neurological disease that affects approximately 6.3 million people, making it the second most common degenerative neurological disorder worldwide1,2.
The severity of PD and how it impacts an individual varies from person to person. The symptoms are predominantly characterized by problems with body movements, called motor symptoms3. These symptoms include tremor, or shaking (often in the hand, arm or leg); rigidity, or stiffness in muscles; slowness of movement, and poor balance and instability3,4. As the disease progresses, these symptoms can worsen to the point where a person becomes dependent on others to perform even basic activities, such as help getting out of a chair and turning over in bed3,5.
Currently there is no cure for PD and symptoms may gradually continue to worsen in the years following diagnosis6. The goal of treatment for PD is to manage motor symptoms, which reduces tremor, rigidity and slowness of movement1.
- DUODOPA® is indicated for treatment of advanced levodopa-responsive PD with severe motor fluctuations and hyper-/dyskinesia when available combinations of PD medicinal products have not given satisfactory results7.
- DUODOPA® provides an effective treatment for people with PD enabling more "ON" time in comparison to oral levodopa7.
- DUODOPA® was approved in recognition of a high unmet need for effective therapies and no satisfactory alternatives8.
- DUODOPA® is contraindicated in patients with narrow-angle glaucoma, severe liver and renal insufficiency, severe heart failure, severe cardiac arrhythmia, suspicious, undiagnosed skin lesions or a history of melanoma, acute stroke and in patients taking non-selective MAO inhibitors and selective MAO type A inhibitors7.
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie employs approximately 25,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com and www.abbvie.ca. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.
1 Mobin A. A comparative analysis of how Michael J. Fox and Muhammad Ali changed the world's views on Parkinson's disease. J Parkinsonism Restless Legs Syndrome 2011;1:1–4.
2 de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006;5:525–35.
3 Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008;79:368–376.
4 Clarke CE. Parkinson's disease. BMJ 2007;335:441–445.
5 ICD9 Data.com. Parkinson's disease 332. Available at: http://www.icd9data.com/2013/Volume1/320-389/330-337/332/default.htm (Last accessed December 2013).
6 Denyer R, Douglas MR. Gene therapy for Parkinson's disease. Parkinsons Dis 2012;2012:757305.
7 AbbVie Limited. Summary of product characteristics: Duodopa intestinal gel, October 2013. Available at: http://www.medicines.org.uk/emc/medicine/20786/SPC/Duodopa+intestinal+gel/ (Last accessed December 2013).
8 European Medicines Agency. Public summary of opinion on orphan designation: levodopa/carbidopa (gastroenteral use) for the treatment of advanced idiopathic Parkinson's disease with severe motor fluctuations and not responding to oral treatment. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2009/10/WC500006499.pdf (Last accessed December 2013).
SYS-CON Events announced today that T-Mobile will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. As America's Un-carrier, T-Mobile US, Inc., is redefining the way consumers and businesses buy wireless services through leading product and service innovation. The Company's advanced nationwide 4G LTE network delivers outstanding wireless experiences to 67.4 million customers who are unwilling to compromise on ...
Mar. 26, 2017 11:00 AM EDT Reads: 2,155
Have you ever noticed how some IT people seem to lead successful, rewarding, and satisfying lives and careers, while others struggle? IT author and speaker Don Crawley uncovered the five principles that successful IT people use to build satisfying lives and careers and he shares them in this fast-paced, thought-provoking webinar. You'll learn the importance of striking a balance with technical skills and people skills, challenge your pre-existing ideas about IT customer service, and gain new in...
Mar. 26, 2017 11:00 AM EDT Reads: 2,494
In his session at @ThingsExpo, Eric Lachapelle, CEO of the Professional Evaluation and Certification Board (PECB), will provide an overview of various initiatives to certifiy the security of connected devices and future trends in ensuring public trust of IoT. Eric Lachapelle is the Chief Executive Officer of the Professional Evaluation and Certification Board (PECB), an international certification body. His role is to help companies and individuals to achieve professional, accredited and worldw...
Mar. 26, 2017 10:45 AM EDT Reads: 596
SYS-CON Events announced today that Juniper Networks (NYSE: JNPR), an industry leader in automated, scalable and secure networks, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Juniper Networks challenges the status quo with products, solutions and services that transform the economics of networking. The company co-innovates with customers and partners to deliver automated, scalable and secure network...
Mar. 26, 2017 10:30 AM EDT Reads: 1,282
SYS-CON Events announced today that Infranics will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Since 2000, Infranics has developed SysMaster Suite, which is required for the stable and efficient management of ICT infrastructure. The ICT management solution developed and provided by Infranics continues to add intelligence to the ICT infrastructure through the IMC (Infra Management Cycle) based on mathemat...
Mar. 26, 2017 10:15 AM EDT Reads: 2,993
SYS-CON Events announced today that SD Times | BZ Media has been named “Media Sponsor” of SYS-CON's 20th International Cloud Expo, which will take place on June 6–8, 2017, at the Javits Center in New York City, NY. BZ Media LLC is a high-tech media company that produces technical conferences and expositions, and publishes a magazine, newsletters and websites in the software development, SharePoint, mobile development and commercial UAV markets.
Mar. 26, 2017 09:30 AM EDT Reads: 4,278
SYS-CON Events announced today that Cloudistics, an on-premises cloud computing company, has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Cloudistics delivers a complete public cloud experience with composable on-premises infrastructures to medium and large enterprises. Its software-defined technology natively converges network, storage, compute, virtualization, and management into a ...
Mar. 26, 2017 09:15 AM EDT Reads: 1,942
SYS-CON Events announced today that Loom Systems will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Founded in 2015, Loom Systems delivers an advanced AI solution to predict and prevent problems in the digital business. Loom stands alone in the industry as an AI analysis platform requiring no prior math knowledge from operators, leveraging the existing staff to succeed in the digital era. With offices in S...
Mar. 26, 2017 09:00 AM EDT Reads: 1,236
Now that the world has connected “things,” we need to build these devices as truly intelligent in order to create instantaneous and precise results. This means you have to do as much of the processing at the point of entry as you can: at the edge. The killer use cases for IoT are becoming manifest through AI engines on edge devices. An autonomous car has this dual edge/cloud analytics model, producing precise, real-time results. In his session at @ThingsExpo, John Crupi, Vice President and Eng...
Mar. 26, 2017 09:00 AM EDT Reads: 3,867
SYS-CON Events announced today that HTBase will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. HTBase (Gartner 2016 Cool Vendor) delivers a Composable IT infrastructure solution architected for agility and increased efficiency. It turns compute, storage, and fabric into fluid pools of resources that are easily composed and re-composed to meet each application’s needs. With HTBase, companies can quickly prov...
Mar. 26, 2017 08:15 AM EDT Reads: 2,876
There are 66 million network cameras capturing terabytes of data. How did factories in Japan improve physical security at the facilities and improve employee productivity? Edge Computing reduces possible kilobytes of data collected per second to only a few kilobytes of data transmitted to the public cloud every day. Data is aggregated and analyzed close to sensors so only intelligent results need to be transmitted to the cloud. Non-essential data is recycled to optimize storage.
Mar. 26, 2017 08:15 AM EDT Reads: 2,979
Historically, some banking activities such as trading have been relying heavily on analytics and cutting edge algorithmic tools. The coming of age of powerful data analytics solutions combined with the development of intelligent algorithms have created new opportunities for financial institutions. In his session at 20th Cloud Expo, Sebastien Meunier, Head of Digital for North America at Chappuis Halder & Co., will discuss how these tools can be leveraged to develop a lasting competitive advanta...
Mar. 26, 2017 08:15 AM EDT Reads: 2,682
"I think that everyone recognizes that for IoT to really realize its full potential and value that it is about creating ecosystems and marketplaces and that no single vendor is able to support what is required," explained Esmeralda Swartz, VP, Marketing Enterprise and Cloud at Ericsson, in this SYS-CON.tv interview at @ThingsExpo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Mar. 26, 2017 08:00 AM EDT Reads: 4,150
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
Mar. 26, 2017 07:15 AM EDT Reads: 1,660
While DevOps most critically and famously fosters collaboration, communication, and integration through cultural change, culture is more of an output than an input. In order to actively drive cultural evolution, organizations must make substantial organizational and process changes, and adopt new technologies, to encourage a DevOps culture. Moderated by Andi Mann, panelists discussed how to balance these three pillars of DevOps, where to focus attention (and resources), where organizations might...
Mar. 26, 2017 05:15 AM EDT Reads: 6,161